Abbreviations: CV, coefficient of variation; conc., concentration; mGWAS, genome-wide association study with metabolic traits, MWAS, metabolome-wide association study, OGTT, oral glucose tolerance test; OLTT, oral lipid tolerance test; PC, phosphatidylcholine; pv, p-value; R, rest that consists of the totality of nonmeasured single PCs, SD, standard deviation 3 Abstract Kit-based assays, such as AbsoluteIDQ TM p150, are widely used in large cohort studies and provide a standardized method to quantify blood concentrations of phosphatidylcholines (PCs). Many disease-relevant associations of PCs were reported using this method. However, their interpretation is hampered by lack of functionally relevant information on the detailed fatty acid side chain compositions as only the total number of carbon atoms and double bonds is identified by the kit. To enable more substantiated interpretations, we characterized these PC sums using the side chain resolving Lipidyzer TM platform, analyzing 223 samples in parallel to the AbsoluteIDQ TM . Combining these datasets, we estimated the quantitative composition of PC sums and subsequently tested their replication in an independent cohort. We identified major constituents of 28 PC sums, revealing also various unexpected compositions. As an example, PC 16:0_22:5 accounted for more than 50% of the PC sum with in total 38 carbon atoms and 5 double bonds (PC aa 38:5). For 13 PC sums, we found relatively high abundances of odd-chain fatty acids. In conclusion, our study provides insights in PC compositions in human plasma, facilitating interpretation of existing epidemiological datasets and potentially enabling imputation of PC compositions for future meta-analyses of lipidomics data.
Introduction
Phosphatidylcholines (PCs) are among the major constituents of eukaryotic cell membranes (1,2) and represent important components of lipoproteins (3) . PCs consist of a polar phosphocholine head group, which is connected via a glycerol backbone to two fatty acid side chains of varying lengths and degree of saturation.
The fatty acids are bound to the sn1 and sn2 positions of the glycerol backbone, either via two ester (acyl) bonds, or by one ester (acyl) and one ether (alkyl) bond. The abundance of PCs in human tissues and its relative abundance compared to other phospholipid classes, such as phosphatidylethanolamines (PEs), has been shown to play an important role in regulating energy metabolism (4) . Furthermore, PC composition (i.e., fatty acid side chain lengths and desaturation levels) influences cell membrane properties, such as their fluidity. As an example, the fluidity of membranes that are made up mainly of PC (16:1/16:1) is higher than that of membranes containing mainly PC (16:0/16:1) or PC (16:0/16:0) (5) . In case of PC (18:0/18:1), the fluidity is maximized when the double bond is located in the Δ9-position (6) . Also for free fatty acids, which can be released from PCs by lipases (7) , "minor" configurational molecular differences, such as in the position of the double bond in the fatty acid chain, can have a major functional impact. For instance, a balanced omega-6/omega-3 fatty acid-ratio of 4/1 associates with 70% lower mortality of patients with cardiovascular diseases (8) .
Today, the availability of modern high throughput lipidomics approaches allows quantification of numerous PCs in thousands of blood samples from epidemiological cohorts. In various large-scale genome-wide and metabolome-wide association studies, many of these PCs have been reported to associate with common genetic variants and various diseases such as Alzheimer's disease (9, 10) , type 2 diabetes (11) (12) (13) , metabolic syndrome (14) , coronary artery disease (15) , and gastric cancer (16) .
While the lipid side chain composition of PCs and the exact configuration of contained fatty acids induce major functional differences, most established lipidomics techniques cannot fully differentiate the specific compounds. Depending on the approach, phospholipids are measured to different degrees of structural resolution, starting at the coarsest level of lipid class/lipid species: For example, based on a precursor ion scan of the mass-to-charge ratio (m/z) 184 (= m/z of the phosphocholine head group), PCs and sphingomyelin (SM) species are selected and further characterized by their total m/z (e.g. PC (731)), which corresponds to the total numbers of carbon atoms and double bonds in the fatty acid side chains (17) . This approach does not allow any differentiation of PC species at the bond-type level, i.e., PCs containing an ether bond (e.g. PC O-33:1) cannot be distinguished from isobaric diacyl-PC species (e.g. PC 32:1). Nonetheless, measures at the lipid level are often annotated with the assumption that even-numbered fatty acids are more common than odd-numbered fatty acids. For instance, PC (731) with m/z 731 covers PC 32:1 and the isobaric PC O-33:1 but is frequently labeled as PC 32:1. In contrast, MS-based lipidomics approaches that, for example, analyze fragmentation spectra can provide measures on the fatty acid level, i.e., they can differentiate between PC O-17:0_16:1 and PC 16:0_16:1. However, usually these fatty acid chain resolving techniques still do not provide any detailed information on the fatty acid position (e.g. PC O-17:0/16:1 versus PC O-16:1/17:0) or on the fatty acid structure (e.g. PC O-17:0/16:1(9Z)) (17, 18) .
The AbsoluteIDQ TM p150 kit (Biocrates Life Sciences AG, Innsbruck, Austria), which has been proven to provide robust, reproducible measurements (19) , has generated large data sets of PCs for epidemiological studies (10, 11, 15, 20, 21) . This method quantifies PCs on the lipid species level and annotates them under the assumption of even-numbered fatty acid chains (e.g. PC aa C32:1 for PC (731) and PC ae C34:1 for PC (745)) with aa indicating two acyl-bound and ae indicating one acyl-and one alkyl-bound fatty acids). As a consequence, only assumptions can be made regarding which specific PCs (i.e., which combination of fatty acid chain lengths and degrees of desaturation) dominate or significantly contribute to the concentration of the measured PC sum (e.g. PC 16:0_16:1, PC 14:1_18:0, and PC O-17:0_16:1 are all examples for possible constituents of PC aa C32:1). Due to the functional implications of fatty acid structures, mechanistic interpretation of observed genetic and disease associations with bulk PC measures is hampered.
In this study, we seek to reveal the fatty acid compositions of PCs in human plasma measured at the lipid species level to facilitate functional interpretation of existing association results. To this end, we combine quantitative data from the AbsoluteIDQ TM p150 and the fatty acid side chain resolving Lipidyzer TM platform powered by Metabolon® (Durham, USA). PC concentrations from both methods have been determined in 223 6 human plasma samples of healthy subjects. To test the transferability of identified PC compositions across different studies, we replicate our results in an independent cohort.
Materials and methods

Human plasma samples
Plasma samples were collected in the Human Metabolome (HuMet) study (22) . The cohort consists of 15 healthy male subjects that have been selected based on following criteria: young age (22-33 y), no medication, and no abnormalities in standard clinical parameters. Participants were submitted to a series of metabolic challenges over four days: extended (36 h) fasting (FASTING) ingesting only 2.7 liters of mineral water, standard liquid mixed meal (SLD) in the form of a fiber-free formula drink supplying one third of their individual recommended daily energy, oral glucose tolerance test (OGTT) with 75 g glucose, physical exercise (PAT) with 30 min on a bicycle ergometer at their personal anaerobic power level, an oral lipid tolerance test (OLTT) with SLD with additional 35 g lipids per square meter of body surface area, and a stress test (STRESS) immersing one hand in ice water for a maximum of three minutes. Blood plasma samples were drawn at 56 different time points before, during and after challenges. All subjects gave their informed consent for inclusion before they participated in the HuMet study. The study protocol was approved by the ethical committee of the Technische Universität München (#2087/08) and corresponds with the Declaration of Helsinki.
In the present study, only 223 samples of four subjects (subject 5subject 8) were analyzed, as only for those data was available from both lipidomics methods.
The Qatar Metabolomics Study on Diabetes (QMDiab), in which we sought replication of our results, is a multi-ethnic diabetes case-control study, with participants aged between 17 and 82 years. Metabolite levels of 305 non-fasting blood plasma samples (152 male, 153 female) measured with both methods were available (23) . All subjects gave their informed consent for inclusion before they participated in the QMDiab study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Boards of HMC and Weill Cornell Medical College-Qatar (Research Protocol number 11131/11).
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Phosphatidylcholine quantification on the lipid species level (AbsoluteIDQ TM p150 kit)
For quantifying lipid sums, HuMet and QMDiab plasma samples were analyzed using the AbsoluteIDQ TM p150 kit (Biocrates Life Sciences AG, Innsbruck, Austria). Besides PCs (including lysophosphatidylcholines (lysoPCs)) and SMs, carnitines, amino acids, and hexoses are quantified by this targeted metabolomics approach. The corresponding analytical procedures have been described in detail before (19, 22) . In brief, 10 µl of human plasma were pipetted onto filter inserts (containing internal standards) in a 96 well plate. The filters were dried under a nitrogen stream, amino acids were derivatized by addition of a phenylisothiocyanate reagent (5%), and samples were dried again. After extraction with 5 mM ammonium acetate in methanol, the solution was centrifuged through a filter membrane and diluted with running solvent. Metabolites were detected by direct infusion to a 4000 QTRAP system (Sciex, Darmstadt, Germany) equipped with a Shimadzu Prominence 
Phosphatidylcholine quantification on the fatty acid level (Lipidyzer TM )
For quantifying lipids resolved at the fatty acid level, plasma samples were analyzed on the Lipidyzer TM platform of AB Sciex Pte. Ltd., Framingham, USA, by Metabolon Inc., Durham, NC, USA. The method allows quantification of over 1100 lipid species from 14 lipid subclasses, including lysoPCs, PCs and SMs (24) (25) (26) (27) (28) .
Lipids were extracted from samples using dichloromethane and methanol in a modified extraction in the presence of internal standards with the lower, organic phase being used for analysis. The extracts were concentrated under nitrogen and reconstituted in 0.25 mL of dichloromethane:methanol (50:50) containing 10 mM ammonium acetate. The extracts were placed in vials for infusion-MS analyses, performed on a Sciex 5500 QTRAP equipped with the SelexION TM differential ion mobility spectrometry (DMS) cell, where ion separation is based on high-field asymmetric wave-form ion mobility mass spectrometry (FAIMS) (30, 31) . This additional device added to the electrospray ionization (ESI) source (applied in positive and negative mode) allows scanning or filtering molecules due to their ion mobility in alternating high and low electric fields before entering the mass spectrometer. With this technology a pre-separation of phospholipid classes (in PCs, lysoPCs, SMs, etc.), independent of their m/z ratio can be achieved. DMS-MS conditions were optimized for phospholipid classes. PCs were detected in negative MRM mode, with characteristic mass fragments for the fatty acid side chains, thus allowing a resolution of the fatty acid composition. In particular, several PC x:y with an odd chain fatty acid are reported by the Lipidyzer TM platform. These are identified by the characteristic fragment of the odd chain fatty acid that cannot be released from an isobaric PC-O x+1:y species with even-numbered side chains. Individual lipid species were quantified based on the ratio of signal intensity for target compounds to the signal intensity for an assigned internal standard of known concentration. For quantification of PCs, 10 stable isotope labeled compounds with a C16:0 fatty acid side chain in the sn-1-position and side chains in the range of C16:1 -C22:6 in the sn-2-position were used as internal standards (25, 32) .
Qualitative description of phosphatidylcholine sums
For assigning PCs measured by Lipidyzer TM to AbsoluteIDQ TM p150 kit PC sums, we first collected all lipid isobars on the fatty acid precision level that can theoretically contribute to the PC x:y sum measure (annotated with PC aa Cx:y in the AbsoluteIDQ TM p150 kit). To this end, we systematically distributed the total numbers of carbon atoms x and double bonds y to the two fatty acid chains, using the short hand notation PC x 1 :y 1 _x 2 :y 2 with x=x 1 +x 2 and y=y 1 +y 2 to indicate that we do not distinguish between the sn-1 and sn-2 positions of the side chains (17) . Additionally, the isobaric compounds PC x+1:y+7, PC O-x+1:y and PC O-x+2:y+7 were considered for PC x:y. Notably, we also included PCs containing odd chain fatty acids or fatty acids with very high desaturation to generate a comprehensive list of isobaric PCs. The software coming with the AbsoluteIDQ TM p150 kit, corrects concentrations of PC sums for the concentration of the (within the mass resolution) isobaric sphingomyelins [ 13 C 1 ]SM x+4:y, if the corresponding SM has been quantified. If the corresponding SM was not quantified by the kit (i.e., no isotope correction has been performed), we included 
Quantitative estimation of phosphatidylcholine sum composition
Both platforms report concentrations of lipid measures in μmol/L. To determine the proportion of a PC at the fatty acid level (measured on the Lipidyzer TM platform) within a PC sum (obtained by the AbsoluteIDQ TM p150 kit), we divided the concentration of the PC j (Lipidyzer TM ) by the concentration of the PC sum PC i (AbsoluteIDQ TM p150 kit) that includes this PC j according to our qualitative assignment ( Supplemental   Table S1 . The characteristic composition of each PC sum is estimated by the mean q ij of the respective ratios q ijst over all subjects s and time points t. The variation was specified as 5
and 95% confidence interval, in which the 5% interval contains the lowest 5% and the 95% interval the largest 5% of the ratio values q ijst . Additionally, we determined fractions of all measured isobaric PCs of the fatty acid level, only using measures from the Lipidyzer TM platform: e.g. PC 16:0_20:2 / (PC 16:0_20:2 + PC 18:0_18:2 + PC 18:1_18:1).
Replication of estimated quantitative phosphatidylcholine compositions in an independent cohort
Replication of estimated proportions q ij (i.e., quotient of PCs of the fatty acid level (j) and the respective PC of the lipid species level (i)) was tested in the subset of 31 non-diabetic (control) male subjects aged between 17 and 40 years of the QMDiab cohort (to restrict the comparison to subjects more similar to the participants of the HuMet cohort). After running the cross-platform comparison of the selected QMDiab samples (as described above), we compared the identified main constituent for all PC sums, for which at least two PCs of the fatty acid level have been measured. In addition, we used a Kruskal-Wallis test (function 'kruskal.test' of R package 'stats' version 3.4.0 (33)) to check if the distributions of proportions q of HuMet-or QMDiab-subjects were significantly different (significance level α = 0.05/37 = 0.0014; with 37 testable PC sums, for which data was available in QMDiab).
Variation of estimated phosphatidylcholine compositions between subjects and challenges
To assess the variation of PC composition within subjects, we determined the average standard deviation (SD) of the ratio q ij observed for samples of the same individual at different timepoints for each PC sum i and PC constituent j. To this end, we considered "baseline" samples (drawn before the challenges), and "intervention" samples (at the timepoint with largest changes of the total metabolome compared to baseline) for each challenge with relation to lipid metabolism: FASTING: baseline at 8 am after 12 h overnight fasting;
intervention at 36 h fasting; PAT: baseline at 4 pm (4 h after last meal); intervention after 30 min exercise;
OLTT: baseline at 8 am after 12 h overnight fasting; intervention at noon. In addition, central trends of the ratio q ij for baseline and intervention timepoints were substantiated by a Wilcoxon signed-rank test (function 'wilcox.test' with options 'two sided' and 'paired' of R package 'stats' version 3.4.0 (33)).
To assess the variation of PC composition between subjects, we determined the average SD of the ratio q ij observed for samples at the same timepoint (baseline and intervention timepoints of each lipid-related challenge) in different subjects for each PC sum i and PC constituent j. We also compared the distributions of q ij from all 56 timepoints of subjects using ANOVA (function 'aov' of R package 'stats' version 3.4.0 (33) 
Estimation of unmapped part of phosphatidylcholine sums
To estimate to what extent the PC bulk measure (in μmol/L) is explained by the sum of all measured PC species (in μmol/L) at the fatty acid level, we applied linear models and Bland-Altman analyses. The formulas for linear models were constructed by PC lipid species level ~ b ⋅ ∑(PC fatty acid level ) and evaluated by the 'lm' function of the R package 'stats', version 3.4.0 (33) .
In the Bland-Altman plots, the difference of PC sums (lipid species level) and cumulated respective measured 
Results
In this study, we aimed at characterizing PC measures at the lipid class/species level by providing qualitative as well as quantitative compositions for these sum measures, which incorporate a variety of PCs at the fatty acid level. Our study is based on data from two targeted lipidomics approaches (AbsoluteIDQ TM p150 kit and Lipidyzer TM platform) for 223 human plasma samples of healthy human subjects. Using the AbsoluteIDQ TM p150 kit, 68 PCs have been quantified in our dataset. Concentrations of in total 109 PCs at the fatty acid level (i.e., providing the bond type as well as the lengths and degree of desaturation for the two fatty acid chains without differentiating between sn-1 and sn-2 positions) have been measured using the Lipidyzer TM platform.
In a first step, we systematically collected all PCs of the fatty acid level that would theoretically fall under each of the 68 PC sums (lipid species level) in a list to provide a comprehensive description of their qualitative compositions. In a second step, we estimated the quantitative composition of 38 of the 68 PC sums for which at least one isobaric PC has been measured on the Lipidyzer TM platform with at least 25% coverage. Identification of the main PC constituent was replicated in an independent cohort for all 19 PC sums, to which more than one constituent on the fatty acid level was assigned. In a third step, we estimated the fraction of PC sums that could not be mapped to any measured PC of the fatty acid level.
Qualitative composition of phosphatidylcholine sums
To map PCs of the fatty acid level to PCs of the lipid species level, we systematically distributed the total numbers of carbon atoms and double bonds to two fatty acid chains for all possible isobaric PCs ( Table 1) . The isobaric sphingomyelin [ 13 C 1 ]SM was also added as a possible compound, if it has not been quantified with the kit and, thus, has not been subtracted from the PC sum measure in the isotope correction step of the AbsoluteIDQ TM p150 kit processing (see Materials and Methods). To each of the 68 measured PC sums of the lipid species level, we thereby assigned between 150 and 456 theoretically possible isobaric compounds of the fatty acid level ( Supplemental Table S1 ). In the supplemental table, we additionally tagged the PCs of the fatty acid level that were considered to be the most probable constituents of the PC sum (2 to 17 PCs per sum) according to Biocrates (34). In this table, we also highlighted those PCs that have been quantified on the Lipidyzer TM platform in our data set and that were assigned to one of the listed 68 PC sums (89 out of 109 PCs). Table S2 ). Here, R corresponds to the sum of respective non-measured PCs of the fatty acid level that are specified in Supplemental Table S1 . In the following, we use the fatty acid level of the short hand notation of lipids for PCs, e.g. PC x 1 :y 1 _x 2 :y 2 according to the resolution of the Lipidyzer TM technique (17) . PCs of the lipid species level are labeled according to the Biocrates-specific notation, e.g. PC aa Cx:y or PC ae Cx:y, corresponding to PC x:y or PC O-x:y although the measurement did not allow differentiation of PCs on the bond type level; PC aa or PC ae labels were chosen under the assumption of even chain lengths of fatty acids.
In a first step, we calculated ratios q ij to estimate the characteristic proportion of each measured PC of the fatty acid level i based on the concentration of the respective PC sum (lipid species level) j in the 223 HuMet samples ( Figure 1A) , and, thus, represent estimates for the proportions of these three species in the PC sum. For 27 out of the 38 investigated PC sums, we identified at least one PC of the fatty acid level with a proportion greater than 20%. For three PC sums, we identified at least two PCs of the fatty acid level with q ij > 0.2. As an example, for PC aa C34:3 the constituents confidence intervals of proportions. The categories "I" and "II" correspond to proportions larger than 0.2 or larger than 0.8 respectively.
Since PC compositions may vary between individuals and depending on fasting state, we calculated and compared the standard deviation (SD) of the ratios q ij of PC constituents separately for different time points (across subjects) and for the different subjects (across timepoints). For this analysis, we focused on baseline and intervention timepoints before and after lipid-related metabolic challenges, namely 36 h fasting (FASTING), physical activity test (PAT), and after ingestion of a lipid-enriched meal OLTT (see Methods), as we expected to observe the largest differences for them. As a result, we observed SD challenges = 0.074 for the average intra-individual variation, and SD subjects = 0.10 for the average inter-individual variation of q ij . No significant trends of the ratios q ij between baseline and intervention timepoints were found for any challenge and any of the main PC constituents. However, the proportions of the main constituents of 13 PC sums were significantly different between subjects ( Supplemental Table S3 ). When comparing the distributions of ratios q ij considering all 56 timepoints, distributions were significantly different between subjects for 18 PC sums. 
Replication of quantitative compositions
To test the transferability of the proportions estimated from the HuMet study ( Figure S2 and Supplemental Table S4 ). In general, estimated proportions (main and others) tended to be higher in samples of QMDiab, compared to HuMet (Figure 2) . Largest differences between proportions in both cohorts were identified for PCs containing C20:4 with the exception of the proportions for PC 15:0_20:4 and PC 17:0_20:4.
Figure 2: Comparison of characteristic proportions in HuMet and QMDiab
On average, proportions tend to be slightly higher in QMDiab than respective proportions in HuMet. The blue lines indicate the threshold where the concentration of the PC constituent measured on the Lipidyzer TM platform was higher than the respective containing PC sum measured with AbsoluteIDQ TM p150 kit. PCs of the fatty acid level that contain C20:4 as one of their lipid side chains are shown as asterisk.
As QMDiab also includes samples from female participants and diabetes patients, we were able to compare proportions of PC constituents between these heterogeneous subgroups. Only for one PC sum, we observed a significant difference for the main (single) PC constituent PC 15:0_20:4 for PC ae C36:4.
Estimation of the contribution of non-measured constituents in phosphatidylcholine sums
Out of 150 to 456 theoretically possible PCs of the fatty acid level per PC sum, the platform comparison only allowed mapping of one to four of these PCs to the respective sums to determine proportions ( Supplemental   Table S1 ). To estimate to which extent each PC sum could be explained by measured PCs of the fatty acid level in our study, we generated linear regression models (estimation of the explained variance; e.g. PC aa C36:2 ~ b ⋅ (PC 16:0_20:2 + PC 18:0_18:2 + PC 18:1_18:1)) and Bland-Altman plots (comparison of absolute concentrations between both analytical methods) for the 38 PCs listed in Table 2 .
In median, 58% (mean: 52%, SD: 28%) of the variance of PC sums could be explained by the corresponding sum of measured PCs of the fatty acid level ( Table 2 and Supplemental Table S5 ). In consequence, 42% of the variance of PC sums was related to further constituents or other factors such as experimental variation.
Since both methods reported metabolite levels in the same quantitative unit (micromolar), we also used Bland-Altman plots to investigate concordance of the PC sum measured on the lipid species level and the sums of constituents measured on the fatty acid level. Notably, here, concordance can only be expected for those PC sums for which all relevant constituents have been measured ( Supplemental Table S2 ). In the plots, we 
Discussion
AbsoluteIDQ TM p150 and p180 kits have emerged as established measurement kits for quantification of phospholipids, such as PCs, in blood from thousands of participants in large epidemiological cohorts (11, 12, 15, 16, 20, (35) (36) (37) (38) (39) and in projects using a variety of human and non-human sample matrices (40) (41) (42) (43) (44) . As the kits quantify PCs on the level of lipid species, each PC measure is composed of isobaric PCs (within mass resolution) with different combinations of fatty acid chain lengths and degrees of desaturation for the two residues. Depending on chain length and desaturation, biochemical properties such as membrane fluidity (5, 6) or lipase activity (7) and, thus, the functions of these constituents, can vary significantly. To facilitate functional interpretation of identified associations between PC sum measures and the outcomes of interest, we In human plasma, the majority of compounds in our reference list indeed are not expected to be present in considerable amounts. Based on the abundance of cellular free fatty acids, it can be assumed that PCs are mainly composed of the even numbered C16:0, C18:0, C18:1, C18:2 and C20:4 fatty acids as the most common fatty acids in human plasma (45) (46) (47) (48) . For 11 PC sums out of 23 PCs labeled as PC aa C32-C40, at least one PC containing two of those fatty acid chains was quantified on the Lipidyzer TM platform in the HuMet cohort. In 8 of the 11 cases, we could confirm the initial assumption as PCs composed of two highly abundant fatty acids were found at higher proportions than other combinations measured with Lipidyzer TM . In 5 cases, those PCs alone accounted for more than 80% of the PC aa measure. However, for three cases, we also found notable exceptions in our data: (i) for PC aa C36:3, PC 16:0_20:3 was more abundant than PC 18:1_18:2;
together they explained more than 80% of the PC sum; (ii) for PC aa C38:5, PC 16:0_22:5 was the major constituent (q ij = 0.55), while PC 18:2_20:4 was only a minor constituent (q ij = 0.098); (iii) for PC aa C38:6, PC 16:0_22:6 was by far the most abundant constituent and explained 77% of the PC sum; PC 18:2_20:4 contributed less to the measured PC sum (q ij = 0.019). Although most proportions for constituents containing C20:4 were significantly larger in the independent QMDiab cohort, we identified the same constituents as major contributors to the corresponding PC sums in all three cases.
As no PCs with ether bonds were measured on the Lipidyzer TM platform in the HuMet cohort, we could not test directly whether the assumption that an alkyl-acyl-PC with even-numbered fatty acid chains were major components for the measures labeled as PC ae. The only constituents for 12 of the 13 PC ae sum measures that have been quantified in our data set were PCs containing an odd-numbered fatty acid chain. On average, proportions of these measured constituents were low (mean q ij = 0.13), suggesting that indeed the not measured isobaric PC-O compounds with two even-numbered fatty acids might account for the major part of the PC sums labeled as PC ae. However, interestingly, we identified 3 PC ae sums containing notable amounts of oddnumbered constituents: PC ae C38:3 with q ij = 0.34 for PC 17:0_20:3, PC ae C36:2 with q ij = 0.23 for PC 17:0_18:2, and PC ae C36:1 with q ij = 0.21 for PC 17:0_18:1.
In 1 of the 13 PC ae sums, namely PC ae C40:1, only PC 18:2_22:6 was measured as possible isobaric constituent (following the rule that PC-O x:y is isobaric with PC x:y+7; see Table 1 ). Notably, the estimated proportion for PC 18:2_22:6 was 0.57 and, thus, this diacyl-PC contributed considerably to the PC sum labeled as the acyl-alkyl-PC PC ae C40:1 in the AbsoluteIDQ TM p150 kit, posing the question whether this measure should rather be annotated with PC aa C40:8.
Due to availability of QMDiab as a replication cohort and of multi-timepoint data in the HuMet cohort, we were able to investigate variation of PC compositions depending on the individual and his/her fasting status.
For various PCs, we observed significant differences in their compositions in terms of the estimated proportion of constituents. In particular, constituents that contained arachidonic acid (C20:4) showed higher proportions in QMDiab. We observed the same trend when analyzing QMDiab subsets (male non-diabetic controls, female non-diabetic controls, and diabetic patients) separately, excluding diabetes as the main reason for this observation. Further factors that could underlie the detected differences in C20:4 abundance between the two cohorts could be general health status (QMDiab diabetics and controls were patients in a dermatological clinic), nutrition, ethnicity, and pre-analytic processing among others. However, despite the observed differences in PC compositions, it has to be noted that the same PCs were identified as main constituents consistently in all subsets that we tested, demonstrating the transferability of our qualitative results to other studies in human plasma.
Limitations
A major limitation in our study is that only for a small number of the possible PC constituents, measures are available on the fatty acid level, preventing a comprehensive overview of the actual compositions. For most PC sums with large cumulative proportions for the measured constituents, the sum of measured constituents also largely explained the variance in the data (R²). However, in some cases, we estimated large proportions, indicating that measured constituents are main parts of the PC sum, but very low R² (e.g. PC aa C42:6 ~ PC 20:0_22:6 with q ij = 0.7 and R² = 5.9%; PC aa C40:3 ~ PC 20:0_20:3 with q ij = 0.5 and R² = 0.2%). The increased variation of proportions q ij observed between subjects may indicate high inter-individual differences in compositions of the respective PC sums. Another reason for the discordance between proportions and explained variance could also result from overestimation of proportions due to differences in extraction and/or ionization efficiency between the two lipidomics approaches. Investigation of such differences in more detail would require measures for all possible (or all relevant) constituents. These differences in extraction and measurement procedures could also explain the estimation of proportions larger than 100% in our data. For four PCs, measured concentrations of constituents on the fatty acid level were much larger than the concentrations of the respective PC sums (lipid species level) with proportions q ij = 1.2 to 1.5.
We used the fatty acid side chain-resolving Lipidyzer TM platform to characterize the molecular constituents of PC sums measured on the lipid species level with an unknown composition of chain lengths and double bonds. Although PC compositions were qualitatively similar across cohorts and timepoints in human plasma samples from healthy and diabetic subjects in the two investigated studies, compositions might be different in other diseases. Also PC compositions identified in this study presumably cannot be readily transferred to other tissues or organisms (49) .
Concluding remarks
By systematically combining measurements from two lipidomics approaches, namely AbsoluteIDQ TM p150 kit and Lipidyzer TM platform, which quantify phosphatidylcholines on different levels of structural resolution, we here unmasked the composition of phosphatidylcholine sum measures in human plasma from healthy subjects.
Knowing the composition of these sums facilitates the interpretation of associations that have been previously identified from the vast amount of data from the AbsoluteIDQ TM p150 kit in large epidemiological cohorts in a more precise biochemical context. In addition, the estimated proportions of constituents, which we determined in our study, might enable imputation of phosphatidylcholines at the fatty acid level based on concentrations of phosphatidylcholine sums to some extent. The possibility of imputation is key to combine studies with data from different lipidomics approaches for large meta-analyses in cases where re-measurement on a side chainresolving lipidomics platform such as Lipidyzer TM is not an option. Supplemental Table S1 : Qualitative composition of PCs measured by AbsoluteIDQ TM p150 kit
Supplemental information
The chain length and double bonds of PCs of the lipid species level were systematically distributed to obtain isobaric molecules of the fatty acid level (150 to 456). If the isobaric sphingomyelin [ 13 C 1 ]SM x+4:y for the PC of the lipid species level PC x:y has not been measured and therefore has not been available for isotope correction, it was also included as possible constituent in the list.
Supplemental Table S2: Isobaric measures from the AbsoluteIDQ TM p150 kit and the Lipidyzer TM platform with ranges of metabolite levels
PCs of the lipid species level, measured by the AbsoluteIDQ TM p150 kit, are compared to the summed levels of related PCs of the fatty acid level measured by Lipidyzer TM . Metabolites marked by an asterisk were excluded because of a missingness >75%.
Supplemental Table S3: Variation of ratios q describing PC compositions
The inter-and intra-individual variation of ratios q of PCs of the fatty acid level (Lipidyzer TM ) and PCs of the lipid species level (AbsoluteIDQ TM p150 kit) was assessed by comparing their distributions.
Supplemental Table S4: Replication of findings in QMDiab
Comparison of compositions of PCs between the HuMet and the QMDiab study and subsets thereof (male controls, female controls and cases) showed that the same PCs of the fatty acid level were identified as major compounds in the two studies.
Supplemental Table S5: Explained variance of PCs of the lipid species level
In median 67.2% (mean: 0.586, SD: 0.277) of the variance of the PCs of the lipid species level (AbsoluteIDQ TM p150 kit) can be explained by the sum of related PCs of the fatty acid level (Lipidyzer TM ).
